Original Article on The New York Times

Filed at 12:29 p.m. ETTRENTON, N.J. (AP) -- Drugmaker Schering-Plough Corp. on Thursday ported lower revenue and a smaller profit in the third quarter, partly due to slightly higher spending on taxes and research.But the company, which soon will become part of much-larger Merck & Co., said that excluding unfavorable currency exchange rates, revenue was up 2 percent at $4.5 billion.The maker of allergy, hepatitis and cholesterol drugs also noted it has just launched three new products in the U.S. or other countries, including the Saphris tablet for schizophrenia and bipolar disorder. That went on sale this month in the U.S.The Kenilworth, N.J.-based company said it had net income of $477 million, down 17 percent from $576 million in last yea...(read more)